ATE370228T1 - Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen - Google Patents
Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagenInfo
- Publication number
- ATE370228T1 ATE370228T1 AT03744903T AT03744903T ATE370228T1 AT E370228 T1 ATE370228 T1 AT E370228T1 AT 03744903 T AT03744903 T AT 03744903T AT 03744903 T AT03744903 T AT 03744903T AT E370228 T1 ATE370228 T1 AT E370228T1
- Authority
- AT
- Austria
- Prior art keywords
- bacteriophages
- bacterium
- lysing
- infecting
- bacteria
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0207021.7A GB0207021D0 (en) | 2002-03-25 | 2002-03-25 | Anti-bacterial agents |
US10/215,056 US20030180319A1 (en) | 2002-03-23 | 2002-08-07 | Antibacterial agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE370228T1 true ATE370228T1 (de) | 2007-09-15 |
Family
ID=28456031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03744903T ATE370228T1 (de) | 2002-03-25 | 2003-03-19 | Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1504088B1 (de) |
JP (1) | JP2005520545A (de) |
CN (1) | CN1643139A (de) |
AT (1) | ATE370228T1 (de) |
AU (1) | AU2003226499A1 (de) |
CA (1) | CA2479897A1 (de) |
DE (1) | DE60315636T2 (de) |
DK (1) | DK1504088T3 (de) |
ES (1) | ES2292996T3 (de) |
WO (1) | WO2003080823A2 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005046579A2 (en) * | 2003-10-06 | 2005-05-26 | Gangagen, Inc. | Defined dose therapeutic phage |
US20060153811A1 (en) * | 2005-01-10 | 2006-07-13 | Jackson Lee E | Use of viruses and virus-resistant microorganisms for controlling microorganism populations |
AU2006268420B2 (en) | 2005-07-12 | 2012-06-28 | Micreos B.V. | Bacteriophage and their uses |
EP2004800B1 (de) * | 2006-04-04 | 2014-01-15 | Henry Morris Krisch | Verfahren zur herstellung von bakteriophagenzusammensetzungen sowie verfahren auf dem gebiet der phagentherapie |
CA2700646C (en) * | 2007-10-04 | 2019-10-29 | Novolytics Limited | Anti-staphylococcus aureus compositions comprising bacteriophage k and p68 |
GB0800149D0 (en) * | 2008-01-04 | 2008-02-13 | Novolytics Ltd | Improved host range phage |
CA2984933C (en) * | 2008-07-03 | 2020-07-07 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
GB2466177A (en) * | 2008-12-03 | 2010-06-16 | Arab Science & Technology Found | Bacteriophage selection and breeding |
RU2580248C9 (ru) * | 2009-02-06 | 2018-01-17 | Текнофахе, Инвестигасао Э Десенвольвименто Эм Биотекнолохия, Са | Бактериофаг, обладащий активностью против pseudomonas aeruginosa, белки бактериофага и способы их применения |
EP2579883A1 (de) * | 2010-06-08 | 2013-04-17 | Leah Robert | Bakteriophagen zur verwendung gegen bakterielle infektionen |
PT3443970T (pt) | 2010-09-17 | 2020-10-09 | Technophage Investig E Desenvolvimento Em Biotecnologia Sa | Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos |
BR112014023321B1 (pt) * | 2012-03-19 | 2022-06-14 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Composições compreendendo fagos antibacterianos e seus usos |
CA2871986C (en) * | 2012-05-04 | 2020-11-03 | Biocontrol Limited | Therapeutic bacteriophage compositions |
GB201402139D0 (en) | 2014-02-07 | 2014-03-26 | Fixed Phage Ltd | Treatment of topical and systemic bacterial infections |
WO2016066722A2 (en) * | 2014-10-28 | 2016-05-06 | Ian Humphery-Smith | Bacteriophage combinations for human or animal therapy |
CN110656093A (zh) * | 2019-10-12 | 2020-01-07 | 山东省农业科学院畜牧兽医研究所 | 一种新型沙门氏菌噬菌体库及其应用 |
CN111826309A (zh) * | 2020-06-30 | 2020-10-27 | 武汉合缘绿色生物股份有限公司 | 一种液体生物营养菌剂及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0895534A1 (de) * | 1996-04-15 | 1999-02-10 | Nymox Corporation | Bakteriophagen enthaltende zusammensetzungen und methoden zur verwendung von bakteriophagen zur behandlung von infektionen |
WO2001051027A2 (en) * | 2000-01-11 | 2001-07-19 | Intralytix, Inc. | Polymer blends as biodegradable matrices for preparing biocomposites |
-
2003
- 2003-03-19 CN CNA038070804A patent/CN1643139A/zh active Pending
- 2003-03-19 DE DE60315636T patent/DE60315636T2/de not_active Expired - Lifetime
- 2003-03-19 AT AT03744903T patent/ATE370228T1/de not_active IP Right Cessation
- 2003-03-19 CA CA002479897A patent/CA2479897A1/en not_active Abandoned
- 2003-03-19 DK DK03744903T patent/DK1504088T3/da active
- 2003-03-19 AU AU2003226499A patent/AU2003226499A1/en not_active Abandoned
- 2003-03-19 ES ES03744903T patent/ES2292996T3/es not_active Expired - Lifetime
- 2003-03-19 WO PCT/GB2003/001190 patent/WO2003080823A2/en active IP Right Grant
- 2003-03-19 EP EP03744903A patent/EP1504088B1/de not_active Expired - Lifetime
- 2003-03-19 JP JP2003578552A patent/JP2005520545A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2003080823A8 (en) | 2004-12-16 |
AU2003226499A1 (en) | 2003-10-08 |
CN1643139A (zh) | 2005-07-20 |
DE60315636D1 (de) | 2007-09-27 |
WO2003080823A3 (en) | 2003-12-11 |
ES2292996T3 (es) | 2008-03-16 |
EP1504088B1 (de) | 2007-08-15 |
EP1504088A2 (de) | 2005-02-09 |
JP2005520545A (ja) | 2005-07-14 |
WO2003080823A2 (en) | 2003-10-02 |
DK1504088T3 (da) | 2007-12-17 |
DE60315636T2 (de) | 2008-05-08 |
CA2479897A1 (en) | 2003-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60315636D1 (de) | Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen | |
Bhattacharya et al. | Surgical site infection by methicillin resistant staphylococcus aureus–On decline? | |
Khosravi et al. | The prevalence of genes encoding leukocidins in Staphylococcus aureus strains resistant and sensitive to methicillin isolated from burn patients in Taleghani Hospital, Ahvaz, Iran | |
Moosavian et al. | Inducible clindamycin resistance in clinical isolates of Staphylococcus aureus due to erm genes, Iran | |
Weiss et al. | Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo | |
Flores-Mireles et al. | Antibody-based therapy for enterococcal catheter-associated urinary tract infections | |
Månsson et al. | Sequence types of Staphylococcus epidermidis associated with prosthetic joint infections are not present in the laminar airflow during prosthetic joint surgery | |
Abdallah et al. | Identification of outer membrane proteins altered in response to UVC-radiation in Vibrio parahaemolyticus and Vibrio alginolyticus | |
Verma et al. | Linezolid attenuates lethal lung damage during postinfluenza methicillin-resistant Staphylococcus aureus pneumonia | |
Abbasi et al. | Antibiotic resistance patterns and virulence determinants of different SCCmec and pulsotypes of Staphylococcus aureus isolated from a major hospital in Ilam, Iran | |
Shariq et al. | Susceptibility profile of methicillin-resistant Staphylococcus aureus to linezolid in clinical isolates | |
WO2004041156A3 (en) | Method for determining sensitivity to a bacteriophage | |
Adeoye-Isijola et al. | Vancomycin intermediate resistant Staphylococcus aureus in the nasal cavity of asymptomatic individuals: a potential public health challenge | |
Rehman et al. | Prevalence and antibiotic susceptibility of clinical staphylococcus aureus isolates in various specimens collected from a tertiary care hospital, Hayatabad, Peshawar, Pakistan.: Antibiotic susceptibility of clinical staphylococcus aureus isolates in various specimens | |
Pardo et al. | Characteristics of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains isolated from skin and soft-tissue infections in Uruguay | |
Riffat | Prevalence, Antibiotic Susceptibility Pat-tern and Demographic Factors Related to Methicillin Resistant Staphy-lococcus aureus in Lahore, Pakistan | |
Mtsher et al. | Estimation of erythromycin and inducible clindamycin resistance in Saphylococcus aureus isolated from clinical cases | |
Anitha et al. | Evaluation of vancomycin minimum inhibitory concentration in the clinical isolates of methicillin resistant Staphylococcus aureus (MRSA) | |
Mbim et al. | Prevalence and antimicrobial susceptibility profile of bacteria isolated from the environment of two tertiary hospitals in Calabar Metropolis, Nigeria | |
Wankhade et al. | Study of antibiotic resistance profiling of Staphylococcus aureus isolated from clinical specimens of the patients attending a tertiary teaching hospital from Chhattisgarh | |
Obajuluwa et al. | Antibiotics susceptibility pattern of coagulase negative staphylococci isolates from orthopaedic patients | |
WO2002086154A8 (en) | Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages | |
Vrbovská et al. | Staphylococcus petrasii diagnostics and its pathogenic potential enhanced by mobile genetic elements | |
Sathish et al. | Prevalence of MRSA in Clinical Samples and their Antibiotic Sensitivity Pattern | |
Gupta et al. | Occurrence of inducible clindamycin resistance in clinical isolates of Staphylococcus aureus in a tertiary care hospital |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |